Columbia’s Dian Yang is placing CRISPR-based molecular recorders into cancer cells to eavesdrop on cancer evolution and pinpoint when and how cells metastasize.
Misinformation and outdated beliefs about screening tests, treatment options, and effects on sexual health continue to cloud understanding about this disease.
The Columbia community gathered in the Hudson Valley for the eighth annual Velocity: Columbia’s Ride to End Cancer. This year’s event raised more than $1 million and attracted nearly 600 participants.
Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
Physician-scientist Juanma Schvartzman is a firm believer that his curiosity-driven research on cell metabolism and its influence on cell identity will offer clues for better cancer treatments.
Combining a diabetes drug with a cancer drug not only kills aggressive bladder cancer cells in mice, but also turns remaining malignant cells into a more benign state.
Lewis Silverman, the new director of pediatric hematology, oncology, and stem cell transplantation, is working to minimize the aftereffects of treatment to ensure the highest quality cure possible.
Columbia researcher Jasmine McDonald, who studies factors that affect the risk of developing breast cancer, discusses what is known about breastfeeding's protective influence on maternal health.
Columbia dermatologist Larisa Geskin discusses the potential dangers of the anti-sunscreen movement and how to protect yourself against the sun's harsh UV rays.
Human embryos often fail to cope with high levels of replication stress early in development. Their failure not only impairs fertility treatment but may have long-ranging impacts on our health.
PARP inhibitors have improved survival of breast cancer patients with BRCA1/2 mutations, but the cancer eventually returns. A Columbia study has now identified a drug that may prevent that relapse.
Four Columbia researchers were awarded pilot grants—made possible by proceeds from Velocity, Columbia’s annual cycling fundraiser—to support their early-stage cancer research.